StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ovid Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Ovid Therapeutics's enterprise value was $343.85M on Nov 11, 2026, against $101.05M a year earlier. Over the last 5 years it ranged from -$49.59M to $343.85M, with a median of $52.80M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$343.85M+280.5%
2025Dec 31, 2025$90.37M+2417.5%
2024Dec 31, 2024$3.59M-97.4%
2023Dec 29, 2023$140.52M–
2022Dec 30, 2022-$6.79M-141.0%
2021Dec 31, 2021$16.55M-72.3%
2020Dec 31, 2020$59.67M-49.3%
2019Dec 31, 2019$117.58M+1543.2%
2018Dec 31, 2018$7.16M-95.1%
2017Dec 29, 2017$146.78M–

More Ovid Therapeutics figures

See a number that looks wrong?